Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...

Mesothelioma is a rare cancer of the membranes that cover the lungs and abdomen. About 3,000 new cases are diagnosed annually ...

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to VT3989, a novel investigational small molecule cancer therapeutic, for the treatment of patients with unresectable ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a human epithelioid mesothelioma cell line, ...

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to ...

For most of the 20th century, asbestos — a naturally occurring mineral — was widely used across all branches of the US ...

Although asbestos use has been restricted for decades, its devastating effects continue to surface—even 40 to 60 years after initial exposure. For hardworking Americans who unknowingly breathed in ...

Primarily associated with asbestos exposure, mesothelioma is a fatal type of cancer most commonly induced by dangerous ...

Knox County veterans are now fighting a battle with an unfair, deadly enemy, decades after their service. A national ...

Scholarship winners Cristian “Brady” Martins and Jennie Betances share their personal experiences with cancer and the impact it had on their lives. The nationally recognized law firm Baron & Budd has ...